Andreas Woerner

Basel, BS, CH 
Basel, BS, CH 
OverviewLocationsClinical Research

Overview

Andreas Woerner practices in Basel, Switzerland. His top areas of expertise are X-Linked Lymphoproliferative Disease, Multisystem Inflammatory Syndrome in Children (MIS-C), Juvenile Idiopathic Arthritis (JIA), and Osteomyelitis in Children.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Basel, BS, Switzerland
Other Locations
Zurich, ZH 8032, Switzerland
Bern, BE, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drugs: Ixekizumab, Adalimumab
Study Phase: Phase 3
Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate (ADA in PiRD)
Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate (ADA in PiRD)
Enrollment Status: Completed
Publish Date: December 01, 2021
Intervention Type: Other
View 1 Less Clinical Trial

31 Total Publications

Influence of Disease Type and Activity on Adalimumab Exposure in Children with Inflammatory Rheumatic Diseases.
Influence of Disease Type and Activity on Adalimumab Exposure in Children with Inflammatory Rheumatic Diseases.
Journal: Journal of clinical pharmacology
Published: December 20, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Woerner's expertise for a condition
ConditionClose
        View All 19 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile